Literature DB >> 9150087

Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status.

N Ruperto1, J E Levinson, A Ravelli, E S Shear, B Link Tague, K Murray, A Martini, E H Giannini.   

Abstract

OBJECTIVE: To assess the long-term health outcomes and quality of life of patients with juvenile rheumatoid arthritis (JRA) using health and functional assessment questionnaires in 2 populations, one from the USA and one from Italy.
METHODS: Patient eligibility criteria: (1) first examined in our units between 1958 and 1990 during the first 6 months after onset of symptoms, (2) diagnosis of JRA by the American College of Rheumatology criteria, (3) disease duration of at least 5 years at the time of assessment of outcome. Instruments used: (1) the Health Assessment Questionnaire (HAQ, short form, or childhood HAQ (CHAQ), and (2) Quality of Life Scales (QOLS, adults only). Eligible patients were identified by computer search and chart review and were then mailed a packet containing a consent/assent form and the assessment instruments.
RESULTS: Of 346 patients who met the eligibility criteria were able to locate 301, and 290 verbally agreed to participate and were mailed packets. Signed consent and complete information were received from 227 of the 290 (78%), 178 from the USA and 49 from Italy. Mean duration of disease at the time of outcome assessment was 15 yrs. 127 had pauciarticular, 55 polyarticular, and 45 systemic onset disease. Mean and (median) scores of the outcomes are shown in the table. [table: see text]
CONCLUSION: Long-term outcome, as assessed by the instruments used, is very favorable in most patients with JRA 5 years or more after onset of symptoms.

Entities:  

Mesh:

Year:  1997        PMID: 9150087

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

Review 1.  Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  World J Pediatr       Date:  2008-08       Impact factor: 2.764

Review 2.  Juvenile idiopathic arthritis: the paediatric perspective.

Authors:  Alison Jordan; Janet E McDonagh
Journal:  Pediatr Radiol       Date:  2006-05-11

3.  Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience.

Authors:  Amieleena Chhabra; Cal Robinson; Kristin Houghton; David A Cabral; Kimberly Morishita; Lori B Tucker; Ross E Petty; Maggie Larché; Michelle Batthish; Jaime Guzman
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

4.  Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.

Authors:  M Halbig; G Horneff
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

5.  Adalimumab for juvenile idiopathic arthritis-associated uveitis.

Authors:  Adriano Magli; Raimondo Forte; Pasqualina Navarro; Giustina Russo; Francesca Orlando; Loredana Latanza; Maria Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-01       Impact factor: 3.117

6.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

7.  Quality of life in the general Norwegian population, measured by the Quality of Life Scale (QOLS-N).

Authors:  Astrid K Wahl; Tone Rustøen; Berit R Hanestad; Anners Lerdal; Torbjørn Moum
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

8.  Juvenile idiopathic arthritis in adulthood and orthopaedic intervention.

Authors:  Ajay Malviya; Sarah Johnson-Lynn; Peter Avery; David Deehan; Helen Foster
Journal:  Clin Rheumatol       Date:  2009-08-30       Impact factor: 2.980

Review 9.  Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy.

Authors:  Ofra Goldzweig; Philip J Hashkes
Journal:  Drug Des Devel Ther       Date:  2011-01-26       Impact factor: 4.162

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.